glp-1/fgf21 agonist boehringer Mechanistic interplay among THRβ agonist, FGF21 analogues and GLP-1RA A novel GLP-1 and FGF21
Description
By 2026, anti-diabetics are expected to attract the third highest level of spending after oncology and immunology treatments
Glucagon-Like Peptide-1 receptor agonist use and residual gastric content before anesthesia
In addition to their effects on - and -cells, GLP-1 analogs reduce hepatic glucose production, appetite, and gastric motility, which are responsible for weight loss
Demand for GLP-1 Receptor Agonists in the global market is estimated to be valued at USD 3 billion in 2026
The addiction signal is the most novel
drug economics
